Allied Investment Advisors LLC Takes Position in Eli Lilly and Company (NYSE:LLY)

Allied Investment Advisors LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 269 shares of the company’s stock, valued at approximately $209,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. PFW Advisors LLC boosted its holdings in Eli Lilly and Company by 1.7% during the first quarter. PFW Advisors LLC now owns 982 shares of the company’s stock worth $764,000 after purchasing an additional 16 shares during the last quarter. BTC Capital Management Inc. acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth about $1,432,000. Gunderson Capital Management Inc. increased its position in shares of Eli Lilly and Company by 6.7% in the first quarter. Gunderson Capital Management Inc. now owns 19,905 shares of the company’s stock valued at $15,485,000 after acquiring an additional 1,247 shares during the last quarter. First Community Trust NA increased its position in shares of Eli Lilly and Company by 390.0% in the first quarter. First Community Trust NA now owns 245 shares of the company’s stock valued at $191,000 after acquiring an additional 195 shares during the last quarter. Finally, Marcum Wealth LLC boosted its position in Eli Lilly and Company by 7.2% during the first quarter. Marcum Wealth LLC now owns 2,917 shares of the company’s stock valued at $2,269,000 after purchasing an additional 196 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Bank of America boosted their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, June 17th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $803.50.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $883.88 on Friday. The firm has a market cap of $840.05 billion, a PE ratio of 130.17, a price-to-earnings-growth ratio of 1.93 and a beta of 0.36. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The stock’s fifty day moving average price is $798.59 and its two-hundred day moving average price is $728.91. Eli Lilly and Company has a one year low of $434.34 and a one year high of $905.45.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. Eli Lilly and Company’s quarterly revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.62 EPS. As a group, research analysts expect that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date was Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 194,978 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the sale, the insider now directly owns 97,583,810 shares of the company’s stock, valued at approximately $86,450,473,117.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold 762,804 shares of company stock valued at $648,109,138 over the last three months. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.